Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedcrizotinib
Educational only, not medical advice. OncoForge makes no claim that Crizotinib treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
1
Preclinical
0
Other
0
1 studies1 review/other
Tracking 1 published study of Crizotinib: 1 reviews/other.
Reported direction across studies: 1 inconclusive.
No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.
These counts summarize what the studies reported; they are not a measure of whether Crizotinib works.
This paper is a review about ALK rearrangements in non-small-cell lung cancer and the drug crizotinib. It summarizes ALK fusion partners, ways to detect ALK rearrangement, and notes that many ALK fusions in NSCLC patients respond well to crizotinib. No new patient data or trial results are reported in the abstract.
Key findings
ALK rearrangements in NSCLC involve multiple fusion partners, including EML4, KIF5B, KLC1, and TPR.
The review states that most ALK fusions in NSCLC patients respond well to the ALK inhibitor crizotinib.
The paper also reviews detection methods for ALK rearrangement.
Limitations: Review article; no original experimental or clinical outcome data in the abstract.; No quantitative results, sample size, dose, or follow-up are reported.; The abstract does not specify the evidence base behind the statement that most ALK fusions respond well to crizotinib..
Background review of an actionable oncogenic alteration and its targeted inhibitor in NSCLC.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Crizotinib's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.